|
rs1187237313
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs200567888
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs370640837
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs61732239
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs757430763
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs772906202
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs121913529
|
|
|
0.020 |
GeneticVariation |
BEFREE |
PTEN loss leads to acceleration of Kras(G12D)-driven pancreatic ductal adenocarcinoma (PDAC) in mice and these tumours have high levels of mammalian target of rapamycin (mTOR) signalling.
|
24717934 |
2014 |
|
rs121913529
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Pancreatic ductal adenocarcinoma (PDAC) commonly contains a mutation in K-Ras(G12D) and is characterized by a desmoplastic reaction composed of deregulated, proliferating cells embedded in an abnormal extracellular matrix (ECM).
|
23555182 |
2013 |
|
rs1444669684
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In LSL-Kras(G12D)/Pdx-1-Cre/Ink4a/Arf(lox/+) mice, calorie restriction versus overweight- or obesity-inducing diet regimens decreased serum IGF-I, tumoral Akt/mTOR signaling, pancreatic desmoplasia, and progression to pancreatic ductal adenocarcinoma (PDAC), and increased pancreatic tumor-free survival.
|
23980075 |
2013 |
|
rs1444669684
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Pancreatic ductal adenocarcinoma (PDAC) commonly contains a mutation in K-Ras(G12D) and is characterized by a desmoplastic reaction composed of deregulated, proliferating cells embedded in an abnormal extracellular matrix (ECM).
|
23555182 |
2013 |
|
rs11571833
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma.
|
30672594 |
2019 |
|
rs17879961
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma.
|
30672594 |
2019 |
|
rs10109853
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Germline DNA from patients who underwent resection for pancreatic ductal adenocarcinoma (n = 79) was sequenced for the IDO2 SNPs R248W and Y359Stop.
|
29426021 |
2018 |
|
rs372883
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genetic variation (rs372883C/T) in the 3'-untranslated region of BTB and CNC homology 1 (<i>BACH1</i>) has been associated with pancreatic ductal adenocarcinoma (PDAC) risk in our previous genome-wide association study; however, the action roles of this genetic variation in PDAC remains unknown.
|
29930735 |
2018 |
|
rs4503083
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Germline DNA from patients who underwent resection for pancreatic ductal adenocarcinoma (n = 79) was sequenced for the IDO2 SNPs R248W and Y359Stop.
|
29426021 |
2018 |
|
rs757797666
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We analysed genetically engineered mouse models and human pancreatic ductal adenocarcinoma (PDAC) cell lines, using a combination of histopathological studies, genome-wide expression and chromatin immunoprecipitation experiments to understand the role of Gata6 in the initiation and progression of KRas(G12V)-driven tumours
|
25596178 |
2016 |
|
rs757238433
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Kras(G12D/+);Trp53(R172H/+);Pdx-1-Cre (KPC) mice, which express an activated form of Kras in pancreatic tissues, develop pancreatic intraepithelial neoplasms (PanIN) that progress to pancreatic ductal adenocarcinoma (PDA).
|
24607504 |
2014 |
|
rs762846821
|
|
|
0.010 |
GeneticVariation |
BEFREE |
PTEN loss leads to acceleration of Kras(G12D)-driven pancreatic ductal adenocarcinoma (PDAC) in mice and these tumours have high levels of mammalian target of rapamycin (mTOR) signalling.
|
24717934 |
2014 |
|
rs1037189404
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present study, we have evaluated stage specific expression patterns of mucins during mouse PC progression in (Kras(G12D);Pdx1-Cre (KC)) murine PC model from pancreatic intraepithelial neoplasia (PanIN) to pancreatic ductal adenocarcinoma (PDAC) by immunohistochemistry and quantitative real-time PCR.
|
23102107 |
2012 |
|
rs1399364791
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The chemopreventive efficacy of the statin atorvastatin (Lipitor(®)) and the role of the phosphatidyl-inositol 3-kinase (PI3/AKT) signaling pathway were evaluated for the progression of pancreatic intraepithelial neoplasms (PanINs) to pancreatic ductal adenocarcinoma (PDAC) in conditional p48(Cre/+) -LSL-Kras(G12D/+) transgenic mice.
|
22287227 |
2012 |
|
rs762581936
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present study, we have evaluated stage specific expression patterns of mucins during mouse PC progression in (Kras(G12D);Pdx1-Cre (KC)) murine PC model from pancreatic intraepithelial neoplasia (PanIN) to pancreatic ductal adenocarcinoma (PDAC) by immunohistochemistry and quantitative real-time PCR.
|
23102107 |
2012 |
|
rs766333007
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present study, we have evaluated stage specific expression patterns of mucins during mouse PC progression in (Kras(G12D);Pdx1-Cre (KC)) murine PC model from pancreatic intraepithelial neoplasia (PanIN) to pancreatic ductal adenocarcinoma (PDAC) by immunohistochemistry and quantitative real-time PCR.
|
23102107 |
2012 |
|
rs1056836
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We analyzed the following CYP1B1 polymorphisms in 129 incident cases of pancreatic ductal adenocarcinoma (PDA): the m1 allele (Val to Leu at codon 432) and the m2 allele (Asn to Ser at codon 453).
|
18347981 |
2008 |
|
rs1800440
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We analyzed the following CYP1B1 polymorphisms in 129 incident cases of pancreatic ductal adenocarcinoma (PDA): the m1 allele (Val to Leu at codon 432) and the m2 allele (Asn to Ser at codon 453).
|
18347981 |
2008 |